| Literature DB >> 28867483 |
Wei Yang1, Søren Berg Padkjær2, Jishu Wang3, Zhe Sun3, Bing Shan3, Li Yang3, Haibin Chen3, Lishan Kang3, Dennis Madsen2, Xun Li3, Chenxi Shen3, Bingke Yu3, Haisun Zhu3, Tzu-Yuan Chao3, Zhuoxiao Cao3, Dapeng Li3, Wei Liu3, Yanping Du3, Jinjing Xu3, Dongxia Hao3, Fengting Xu3, Lujia Peng3, Tengkun Li3, Lin Wang3, Lin Li3, Haimei Xing3, Di Liu3, Zibing Liu3, Zhishuang Guan3, Wan Wang3, Hong Cheng3, Henrik Østergaard2, Chihchuan Chang3, Zhiru Yang3, Esper Boel2, Jing Su3.
Abstract
Interactions between protein ligands and receptors play crucial roles in cell-cell signalling. Most of the human cell surface receptors have been identified in the post-Human Genome Project era but many of their corresponding ligands remain unknown. To facilitate the pairing of orphan receptors, 2762 sequences encoding all human single-pass transmembrane proteins were selected for inclusion into a mammalian-cell expression library. This expression library, consisting of all the individual extracellular domains (ECDs), was constructed as a Fab fusion for each protein. In this format, individual ECD can be produced as a soluble protein or displayed on cell surface, depending on the applied heavy-chain Fab configuration. The unique design of the Fab fusion concept used in the library led to not only superior success rate of protein production, but also versatile applications in various high-throughput screening paradigms including protein-protein binding assays as well as cell binding assays, which were not possible for any other existing expression libraries. The protein library was screened against human coagulation factor VIIa (FVIIa), an approved therapeutic for the treatment of hemophilia, for binding partners by AlphaScreen and ForteBio assays. Two previously known physiological ligands of FVIIa, tissue factor (TF) and endothelial protein C receptor (EPCR) were identified by both assays. The cell surface displayed library was screened against V-domain Ig suppressor of T-cell activation (VISTA), an important immune-checkpoint regulator. Immunoglobulin superfamily member 11 (IgSF11), a potential target for cancer immunotherapy, was identified as a new and previously undescribed binding partner for VISTA. The specificity of the binding was confirmed and validated by both fluorescence-activated cell sorting (FACS) and surface plasmon resonance (SPR) assays in different experimental setups.Entities:
Keywords: Expression library; Fab; High-throughput screening; IgSF11; VISTA
Mesh:
Substances:
Year: 2017 PMID: 28867483 DOI: 10.1016/j.jbiotec.2017.08.023
Source DB: PubMed Journal: J Biotechnol ISSN: 0168-1656 Impact factor: 3.307